Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyclezyme ABXSAT:CYCLE -2.05%8 Market Cap is kr61.90 Mil as of Jul. 14, 2026. GuruFocus rates XSAT:CYCLE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 1,632 Chemicals companies, Cyclezyme AB ranks worse than 92.46% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cyclezyme AB's share price for the quarter that ended in Mar. 2026 was kr12.8. Cyclezyme AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2.59 Mil. Therefore, Cyclezyme AB's market cap for the quarter that ended in Mar. 2026 was kr33.15 Mil.
Cyclezyme AB's quarterly market cap
declined
from Sep. 2025 (kr42.46 Mil) to Dec. 2025 (kr41.05 Mil) and
declined
from Dec. 2025 (kr41.05 Mil) to Mar. 2026 (kr33.15 Mil).
Cyclezyme AB's annual market cap
increased
from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr15.52 Mil) and
increased
from Dec. 2024 (kr15.52 Mil) to Dec. 2025 (kr41.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cyclezyme AB's Enterprise Value for Today is kr60.38 Mil.
Cyclezyme AB (XSAT:CYCLE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cyclezyme AB Market Cap Related Terms
Cyclezyme AB Market Cap Historical Data
* Premium members only.
The historical data trend for Cyclezyme AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CYCLE vs LIN, SHW, ECL: Market Cap Comparison
For the Specialty Chemicals subindustry, Cyclezyme AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclezyme AB Market Cap vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Cyclezyme AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Cyclezyme AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cyclezyme AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclezyme AB (XSAT:CYCLE) has a Market Cap of kr61.90 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cyclezyme AB and its competitors. According to the industry distribution chart, Cyclezyme AB ranks #1509 out of 1632 companies in the Chemicals industry, placing it in the top 92.5%.
Is Cyclezyme AB's Market Cap too high?
Cyclezyme AB's current Market Cap is kr61.90 Mil. Based on the distribution chart, Cyclezyme AB ranks #1509 out of 1632 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Cyclezyme AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Cyclezyme AB's Market Cap compare to LIN and SHW?
According to the Chemicals industry distribution chart, Cyclezyme AB ranks #1509 out of 1632 companies for Market Cap. This places Cyclezyme AB in the lower half of its industry. The industry median Market Cap is 289.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Chemicals company?
The median Market Cap among Chemicals companies is 289.34, based on 1,632 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cyclezyme AB and its competitors. For the Chemicals industry, the median Market Cap is 289.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclezyme AB's current Market Cap is kr61.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclezyme AB stock overvalued right now?
Cyclezyme AB (XSAT:CYCLE) has a current Market Cap of kr61.90 Mil. The current Market Cap is kr61.90 Mil. Cyclezyme AB's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cyclezyme AB (XSAT:CYCLE), the current Market Cap is kr61.90 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
8GF Score
Get the complete analysis for XSAT:CYCLE
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CYCLE has been successfully added to your 
